Home › Compare › BLPH vs EQR

BLPH vs EQR: Dividend Comparison 2026

BLPH yields 158.04% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BLPH wins by $32.64M in total portfolio value
10 years
BLPH
BLPH
● Live price
158.04%
Share price
$0.01
Annual div
$0.02
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.68M
Annual income
$14,560,088.59
Full BLPH calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — BLPH vs EQR

📍 BLPH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBLPHEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BLPH + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BLPH pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BLPH
Annual income on $10K today (after 15% tax)
$13,433.54/yr
After 10yr DRIP, annual income (after tax)
$12,376,075.30/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, BLPH beats the other by $12,372,828.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BLPH + EQR for your $10,000?

BLPH: 50%EQR: 50%
100% EQR50/50100% BLPH
Portfolio after 10yr
$16.36M
Annual income
$7,281,954.10/yr
Blended yield
44.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

BLPH
Analyst Ratings
7
Buy
1
Hold
Consensus: Buy
Altman Z
-77.3
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BLPH buys
0
EQR buys
0
No recent congressional trades found for BLPH or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBLPHEQR
Forward yield158.04% ✓4.73%
Annual dividend / share$0.02$2.77 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$32.68M$40.5K ✓
Annual income after 10y$14,560,088.59 ✓$3,819.61
Total dividends collected$30.36M ✓$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: BLPH vs EQR ($10,000, DRIP)

YearBLPH PortfolioBLPH Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$26,504$15,804.17$11,248$547.57+$15.3K → BLPH
2$67,507$39,147.31$12,701$666.53+$54.8K → BLPH
3$165,418$93,186.16$14,405$814.59+$151.0K → BLPH
4$390,402$213,404.75$16,413$999.84+$374.0K → BLPH
5$888,436$470,705.22$18,795$1,232.92+$869.6K → BLPH
6$1,951,729$1,001,103.05$21,639$1,527.95+$1.93M → BLPH
7$4,143,713$2,055,363.02$25,057$1,903.80+$4.12M → BLPH
8$8,512,033$4,078,259.67$29,197$2,385.87+$8.48M → BLPH
9$16,937,387$7,829,511.79$34,250$3,008.70+$16.90M → BLPH
10$32,683,093$14,560,088.59$40,467$3,819.61+$32.64M → BLPH

BLPH vs EQR: Complete Analysis 2026

BLPH — Stock

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Full BLPH Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this BLPH vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BLPH vs SCHDBLPH vs JEPIBLPH vs OBLPH vs KOBLPH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.